{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T12:44:32Z","timestamp":1790426672503,"version":"4.1.0"},"reference-count":27,"publisher":"American Society of Hematology","issue":"10","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,3,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The role of allogeneic stem cell transplantation in chronic myeloid leukemia is being reevaluated. Whereas drug treatment has been shown to be superior in first-line treatment, data on allogeneic hematopoietic stem cell transplantation (allo SCT) as second-line therapy after imatinib failure are scarce. Using an interim safety analysis of the randomized German CML Study IV designed to optimize imatinib therapy by combination, dose escalation, and transplantation, we here report on 84 patients who underwent consecutive transplantation according to predefined criteria (low European Group for Blood and Marrow Transplantation [EBMT] score, imatinib failure, and advanced disease). Three-year survival after transplantation of 56 patients in chronic phase was 91% (median follow-up: 30 months). Transplantation-related mortality was 8%. In a matched pair comparison of patients who received a transplant and those who did not, survival was not different. Three-year survival after transplantation of 28 patients in advanced phase was 59%. Eighty-eight percent of patients who received a transplant achieved complete molecular remissions. We conclude that allo SCT could become the preferred second-line option after imatinib failure for suitable patients with a donor. The study is registered at the National Institutes of Health, http:\/\/clinicaltrials.gov: NCT00055874.<\/jats:p>","DOI":"10.1182\/blood-2009-08-237115","type":"journal-article","created":{"date-parts":[[2009,11,18]],"date-time":"2009-11-18T21:42:14Z","timestamp":1258580534000},"page":"1880-1885","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":170,"title":["Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV"],"prefix":"10.1182","volume":"115","author":[{"given":"Susanne","family":"Saussele","sequence":"first","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Lauseker","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Medizinische Informationsverarbeitung (IBE), Universit\u00e4t M\u00fcnchen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alois","family":"Gratwohl","sequence":"additional","affiliation":[{"name":"H\u00e4matologie, Universit\u00e4tsspital Basel, Basel, Switzerland;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietrich W.","family":"Beelen","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Knochenmarktransplantation, Universit\u00e4tsklinikum der Universit\u00e4t Duisburg-Essen, Duisburg-Essen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Bunjes","sequence":"additional","affiliation":[{"name":"Klinik f\u00fcr Innere Medizin III, Universit\u00e4tsklinikum Ulm, Ulm, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rainer","family":"Schwerdtfeger","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Knochenmarktransplantation, Deutsche Klinik f\u00fcr Diagnostik (DKD), Wiesbaden, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hans-Jochem","family":"Kolb","sequence":"additional","affiliation":[{"name":"Medizinische Klinik III, Klinikum Gro\u00dfhadern, Universit\u00e4t M\u00fcnchen, M\u00fcnchen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Ho","sequence":"additional","affiliation":[{"name":"Medizinische Klinik V, Ruprecht-Karls-Universit\u00e4t Heidelberg, Heidelberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Falge","sequence":"additional","affiliation":[{"name":"Klinikum Nord, N\u00fcrnberg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernst","family":"Holler","sequence":"additional","affiliation":[{"name":"Universit\u00e4tsklinikum Regensburg, Regensburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcnter","family":"Schlimok","sequence":"additional","affiliation":[{"name":"II Medizinische Klinik, Zentralklinikum Augsburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Axel R.","family":"Zander","sequence":"additional","affiliation":[{"name":"Zentrum f\u00fcr Knochenmarktransplantation (KMT), Universit\u00e4tsklinikum Hamburg-Eppendorf, Hamburg-Eppendorf, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renate","family":"Arnold","sequence":"additional","affiliation":[{"name":"Charit\u00e9 Universit\u00e4tsmedizin Berlin, Berlin, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lothar","family":"Kanz","sequence":"additional","affiliation":[{"name":"Innere Medizin II, Universit\u00e4tsklinikum T\u00fcbingen, T\u00fcbingen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Dengler","sequence":"additional","affiliation":[{"name":"H\u00e4matologisch-onkologische Praxis, Regensburg, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudia","family":"Haferlach","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Schlegelberger","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Zell-und Molekularpathologie, Medizinische Hochschule Hannover (MHH), Hannover, Germany; and"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Pfirrmann","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Medizinische Informationsverarbeitung (IBE), Universit\u00e4t M\u00fcnchen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin C.","family":"M\u00fcller","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanne","family":"Schnittger","sequence":"additional","affiliation":[{"name":"MLL Munich Leukemia Laboratory, Munich, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armin","family":"Leitner","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadine","family":"Pletsch","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andreas","family":"Hochhaus","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"},{"name":"Klinik f\u00fcr Innere Medizin II, Universit\u00e4tsklinikum, Jena, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joerg","family":"Hasford","sequence":"additional","affiliation":[{"name":"Institut f\u00fcr Medizinische Informationsverarbeitung (IBE), Universit\u00e4t M\u00fcnchen, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R\u00fcdiger","family":"Hehlmann","sequence":"additional","affiliation":[{"name":"III Medizinische Klinik, Medizinische Fakult\u00e4t Mannheim der Universit\u00e4t Heidelberg, Mannheim, Germany;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the German CML Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"9584","key":"2019111721502370500_B1","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1016\/S0140-6736(07)61165-9","article-title":"Chronic myeloid leukaemia.","volume":"370","author":"Hehlmann","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"2019111721502370500_B2","first-page":"513","article-title":"Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results: an analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT).","volume":"91","author":"Gratwohl","year":"2006","journal-title":"Haematologica"},{"issue":"12","key":"2019111721502370500_B3","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s00277-009-0737-3","article-title":"The changing scene of allogeneic stem cell transplantation for chronic myeloid leukemia\u2013a report from the German Registry covering the period from 1998 to 2004.","volume":"88","author":"Bacher","year":"2009","journal-title":"Ann Hematol"},{"issue":"8","key":"2019111721502370500_B4","doi-asserted-by":"crossref","first-page":"3500","DOI":"10.1182\/blood-2008-02-141689","article-title":"Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.","volume":"112","author":"Lee","year":"2008","journal-title":"Blood"},{"issue":"4","key":"2019111721502370500_B5","first-page":"452","article-title":"The effect of prior exposure to imatinib on transplant-related mortality.","volume":"91","author":"Deininger","year":"2006","journal-title":"Haematologica"},{"issue":"2","key":"2019111721502370500_B6","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.22778","article-title":"Novel tyrosine kinase inhibitor therapy before allogeneic stem cell transplantation in patients with chronic myeloid leukemia: no evidence for increased transplant-related toxicity.","volume":"110","author":"Jabbour","year":"2007","journal-title":"Cancer"},{"issue":"4","key":"2019111721502370500_B7","doi-asserted-by":"crossref","first-page":"1782","DOI":"10.1182\/blood-2006-06-031682","article-title":"The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia.","volume":"109","author":"Oehler","year":"2007","journal-title":"Blood"},{"issue":"5","key":"2019111721502370500_B8","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1111\/j.1365-2141.2007.06582.x","article-title":"Impact of imatinib therapy on the use of allogeneic haematopoietic progenitor cell transplantation for the treatment of chronic myeloid leukaemia.","volume":"137","author":"Giralt","year":"2007","journal-title":"Br J Haematol"},{"issue":"1","key":"2019111721502370500_B9","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1038\/leu.2008.160","article-title":"Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT toxicity in patients with chronic myelogenous leukemia and Philadelphia positive acute lymphoblastic leukemia.","volume":"23","author":"Shimoni","year":"2009","journal-title":"Leukemia"},{"issue":"11","key":"2019111721502370500_B10","first-page":"186a","article-title":"International Randomized Study of Interferon Versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CMLCP) treated with imatinib (IM) [abstract].","volume":"112","author":"O'Brien","year":"2008","journal-title":"Blood (ASH Annual Meeting Abstracts)"},{"issue":"8","key":"2019111721502370500_B11","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1038\/sj.leu.2403426","article-title":"Imatinib therapy in chronic myelogenous leukemia: strategies to avoid and overcome resistance.","volume":"18","author":"Hochhaus","year":"2004","journal-title":"Leukemia"},{"issue":"11","key":"2019111721502370500_B12","doi-asserted-by":"crossref","first-page":"4686","DOI":"10.1182\/blood-2006-11-055186","article-title":"Drug treatment is superior to allografting as first line therapy in chronic myeloid leukemia.","volume":"109","author":"Hehlmann","year":"2007","journal-title":"Blood"},{"issue":"3","key":"2019111721502370500_B13","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1038\/sj.leu.2404100","article-title":"Cytogenetic response to prior treatment with interferon-alpha is predictive for survival after allogeneic hematopoietic stem cell transplantation in chronic myeloid leukemia.","volume":"20","author":"Maywald","year":"2006","journal-title":"Leukemia"},{"key":"2019111721502370500_B14","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.184.184","article-title":"Randomized comparison of imatinib 400 mg vs. imatinib + IFN vs. imatinib + araC vs. imatinib after IFN vs. imatinib 800 mg: optimized treatment and survival: designed first interim analysis of the German CML Study IV [abstract].","volume":"112","author":"Hehlmann","year":"2008","journal-title":"Blood"},{"issue":"11","key":"2019111721502370500_B15","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/jnci\/90.11.850","article-title":"A new prognostic score for the survival of patients with chronic myeloid leukemia treated with interferon alfa.","volume":"90","author":"Hasford","year":"1998","journal-title":"J Natl Cancer Inst"},{"issue":"9134","key":"2019111721502370500_B16","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0140-6736(98)03030-X","article-title":"Risk assessment for patients with chronic myeloid leukemia before allogeneic blood or marrow transplantation.","volume":"352","author":"Gratwohl","year":"1998","journal-title":"Lancet"},{"issue":"6","key":"2019111721502370500_B17","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet.","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111721502370500_B18","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/(SICI)1097-0258(19990330)18:6<695::AID-SIM60>3.0.CO;2-O","article-title":"Estimation of failure probabilities in the presence of competing risks: new representations of old estimators.","volume":"18","author":"Gooley","year":"1999","journal-title":"Stat Med"},{"issue":"1","key":"2019111721502370500_B19","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1182\/blood-2006-01-0092","article-title":"Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for \u2018harmonizing\u2019 current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results.","volume":"108","author":"Hughes","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111721502370500_B20","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1182\/blood.V82.6.1929.1929","article-title":"Competitive polymerase chain reaction to estimate the number of BCR-ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation.","volume":"82","author":"Cross","year":"1993","journal-title":"Blood"},{"issue":"4","key":"2019111721502370500_B21","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1182\/blood.V63.4.789.bloodjournal634789","article-title":"Prognostic discrimination in \u201cgood-risk\u201d chronic granulocytic leukemia.","volume":"63","author":"Sokal","year":"1984","journal-title":"Blood"},{"issue":"2","key":"2019111721502370500_B22","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/j.1365-2141.2008.07179.x","article-title":"Treosulfan and fludarabine low-toxicity conditioning for allogeneic haematopoietic stem cell transplantation in chronic myeloid leukaemia.","volume":"142","author":"Holowiecki","year":"2008","journal-title":"Br J Haematol"},{"issue":"3","key":"2019111721502370500_B23","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1002\/cncr.24026","article-title":"The extent of minimal residual disease reduction after the first 4-week imatinib therapy determines outcome of allogeneic stem cell transplantation in adults with Philadelphia chromosome-positive acute lymphoblastic leukemia.","volume":"115","author":"Lee","year":"2009","journal-title":"Cancer"},{"issue":"5","key":"2019111721502370500_B24","doi-asserted-by":"crossref","first-page":"2163","DOI":"10.1182\/blood-2008-04-148130","article-title":"Association between BMI-1 expression, acute graft-versus-host disease, and outcome following allogeneic stem cell transplantation from HLA-identical siblings in chronic myeloid leukemia.","volume":"112","author":"Mohty","year":"2008","journal-title":"Blood"},{"issue":"13","key":"2019111721502370500_B25","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1016\/j.molimm.2008.04.016","article-title":"KIR2DS5 is associated with leukemia free survival after HLA identical stem cell transplantation in chronic myeloid leukemia patients.","volume":"45","author":"van der Meer","year":"2008","journal-title":"Mol Immunol"},{"issue":"12","key":"2019111721502370500_B26","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.3324\/haematol.13068","article-title":"Chronic myeloid leukemia in blast crisis treated with imatinib 600 mg: outcome of the patients alive after a 6-year follow-up.","volume":"93","author":"Palandri","year":"2008","journal-title":"Haematologica"},{"issue":"12","key":"2019111721502370500_B27","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.3324\/haematol.2008.001214","article-title":"Treatment of chronic myeloid leukemia in blast crisis.","volume":"93","author":"Hehlmann","year":"2008","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/115\/10\/1880\/1324494\/zh801010001880.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/115\/10\/1880\/1324494\/zh801010001880.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,23]],"date-time":"2020-05-23T15:30:06Z","timestamp":1590247806000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/115\/10\/1880\/26843\/Allogeneic-hematopoietic-stem-cell-transplantation"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,3,11]]},"references-count":27,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,3,11]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2009-08-237115","relation":{"has-review":[{"id-type":"doi","id":"10.3410\/f.2699957.2362055","asserted-by":"object"}]},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,3,11]]}}}